Calcium, Phosphate, PTH, Vitamin D and FGF-23 in Chronic Kidney Disease

Nutritional Management of Renal Disease

Volumn , Issue , 2013, Pages 263-283

  Voinescu, Alexandra ^a   Martin, Kevin J ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884119737     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391934-2.00019-9     Document Type: Chapter

References (209)

1. van de Graaf S.F., Hoenderop J.G., Bindels R.J. Regulation of TRPV5 and TRPV6 by associated proteins. Am J Physiol Renal Physiol 2006, 290(6). F1295-302.
2. van Abel M., et al. Coordinated control of renal Ca(2+) transport proteins by parathyroid hormone. Kidney Int 2005, 68(4):1708-1721.
3. 2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003, 112(12):1906-1914.
4. 2+ and 1, 25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. FASEB J 2002, 16(11):1398-1406.
5. Van Abel M., et al. 1, 25-dihydroxyvitamin D(3)-independent stimulatory effect of estrogen on the expression of ECaC1 in the kidney. J Am Soc Nephrol 2002, 13(8):2102-2109.
6. Omdahl J.L., Morris H.A., May B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002, 22:139-166.
7. Lowe K.E., Maiyar A.C., Norman A.W. Vitamin D-mediated gene expression. Crit Rev Eukaryot Gene Expr 1992, 2(1):65-109.
8. Ozono K., Sone T., Pike J.W. The genomic mechanism of action of 1, 25-dihydroxyvitamin D3. J Bone Miner Res 1991, 6(10):1021-1027.
9. Moe S. Disorders of phosphate metabolism in CKD. Calcium and Phosphate Management in Chronic Kidney Disease 2010, Springer, p. 13-28. C. Hsu (Ed.).
10. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 2007, 20(4):295-301.
11. Moe S.M., Sprague S.M. Chronic Kidney Disease-Mineral Bone Disorder. The Kidney 2011, 2021-2049. Elsevier Saunders.
12. Craver L., et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007, 22(4):1171-1176.
13. Harrison H.E., Harrison H.C. Intestinal transport of phosphate: action of vitamin D, calcium, and potassium. Am J Physiol 1961, 201:1007-1012.
14. Hilfiker H., et al. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci U S A 1998, 95(24):14564-14569.
15. Marks J., Debnam E.S., Unwin R.J. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010, 299(2). F285-96.
16. Sabbagh Y., et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009, 20(11):2348-2358.
17. Capuano P., et al. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor- and 1alphaOHase-deficient mice. Am J Physiol Cell Physiol 2005, 288(2). C429-34.
18. Katai K., et al. Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1, 25-dihydroxyvitamin D3. Biochem J 1999, 343(Pt 3):705-712.
19. Borowitz S.M., Granrud G.S. Glucocorticoids inhibit intestinal phosphate absorption in developing rabbits. J Nutr 1992, 122(6):1273-1279.
20. Marks J., et al. Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol 2008, 19(12):2313-2320.
21. Miyamoto K., et al. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 2005, 9(4):331-335.
22. Stauber A., et al. Regulation of intestinal phosphate transport. II. Metabolic acidosis stimulates Na(+)-dependent phosphate absorption and expression of the Na(+)-P(i) cotransporter NaPi-IIb in small intestine. Am J Physiol Gastrointest Liver Physiol 2005, 288(3). G501-6.
23. Xu H., et al. Regulation of the human sodium-phosphate cotransporter NaP(i)-IIb gene promoter by epidermal growth factor. Am J Physiol Cell Physiol 2001, 280(3). C628-36.
24. Xu H., et al. Regulation of intestinal NaPi-IIb cotransporter gene expression by estrogen. Am J Physiol Gastrointest Liver Physiol 2003, 285(6). G1317-24.
25. Beck L., et al. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 1998, 95(9):5372-5377.
26. Segawa H., et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 2009, 297(3). F671-8.
27. Tenenhouse H.S., et al. Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol 2003, 285(6). F1271-8.
28. Villa-Bellosta R., et al. The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. Am J Physiol Renal Physiol 2009, 296(4). F691-9.
29. Bianda T., et al. Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1, 25 dihydroxyvitamin D3 production in healthy man. J Intern Med 1997, 241(2):143-150.
30. Ishiguro M., et al. Thyroid hormones regulate phosphate homoeostasis through transcriptional control of the renal type IIa sodium-dependent phosphate co-transporter (Npt2a) gene. Biochem J 2010, 427(1):161-169.
31. Kurnik B.R., Hruska K.A. Mechanism of stimulation of renal phosphate transport by 1, 25-dihydroxycholecalciferol. Biochim Biophys Acta 1985, 817(1):42-50.
32. Ambuhl P.M., et al. Regulation of renal phosphate transport by acute and chronic metabolic acidosis in the rat. Kidney Int 1998, 53(5):1288-1298.
33. Blaine J., Weinman E.J., Cunningham R. The regulation of renal phosphate transport. Adv Chronic Kidney Dis 2011, 18(2):77-84.
34. Laron Z., Crawford J.D., Klein R. Phosphaturic effect of cortisone in normal and parathyroidectomized rats. Proc Soc Exp Biol Med 1957, 96(3):649-651.
35. Pfister M.F., et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci U S A 1998, 95(4):1909-1914.
36. Prie D., Urena Torres P., Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009, 75(9):882-889.
37. Berndt T., et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003, 112(5):785-794.
38. Cai Q., et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994, 330(23):1645-1649.
39. Jonsson K.B., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003, 348(17):1656-1663.
40. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 2000, 27(3):333-338.
41. Rowe P.S., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34(2):303-319.
42. Shimada T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98(11):6500-6505.
43. White K.E., et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26(3):345-348.
44. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000, 277(2):494-498.
45. Liu S., et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, 278(39):37419-37426.
46. Liu S., et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 291(1). E38-49.
47. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006, 15(4):437-441.
48. Shimada T., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19(3):429-435.
49. Shimada T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113(4):561-568.
50. Kurosu H., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281(10):6120-6123.
51. Urakawa I., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444(7120):770-774.
52. Kuro-o M., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390(6655):45-51.
53. Segawa H., et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 2007, 292(2). F769-79.
54. Ben-Dov I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117(12):4003-4008.
55. Krajisnik T., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195(1):125-131.
56. Ferrari S.L., Bonjour J.P., Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005, 90(3):1519-1524.
57. Liu S., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17(5):1305-1315.
58. Nakai K., Komaba H., Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol 2010, 23(6):619-625.
59. Nishida Y., et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006, 70(12):2141-2147.
60. Perwad F., et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146(12):5358-5364.
61. Lorenz-Depiereux B., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006, 38(11):1248-1250.
62. Collins M.T., et al. Fibroblast growth factor-23 is regulated by 1alpha, 25-dihydroxyvitamin D. J Bone Miner Res 2005, 20(11):1944-1950.
63. Hines E.R., et al. 1, 25-dihydroxyvitamin D3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J Biol Chem 2004, 279(45):46406-46414.
64. Liu S., Quarles L.D. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007, 18(6):1637-1647.
65. Ramon I., et al. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol 2010, 162(1):1-10.
66. Saito H., et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005, 280(4):2543-2549.
67. Levin A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71(1):31-38.
68. Hruska K.A., et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008, 74(2):148-157.
69. Komaba H., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010, 77(3):232-238.
70. Martin K.J., Gonzalez E.A. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?. Clin J Am Soc Nephrol 2011, 6(2):440-446.
71. Silver J., Naveh-Many T. Phosphate and the parathyroid. Kidney Int 2009, 75(9):898-905.
72. Tsujikawa H., et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17(12):2393-2403.
73. Almaden Y., et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996, 11(7):970-976.
74. Nielsen P.K., Feldt-Rasmussen U., Olgaard K. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 1996, 11(9):1762-1768.
75. Slatopolsky E., et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996, 97(11):2534-2540.
76. Almaden Y., et al. Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 2000, 11(9):1712-1718.
77. Ritter C.S., et al. Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 2002, 17(12):2206-2213.
78. Cozzolino M., et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 2005, 289(5). F1096-102.
79. Silver J., et al. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int Suppl 1999, 73:S2-S7.
80. Yalcindag C., Silver J., Naveh-Many T. Mechanism of increased parathyroid hormone mRNA in experimental uremia: roles of protein RNA binding and RNA degradation. J Am Soc Nephrol 1999, 10(12):2562-2568.
81. Dhingra R., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167(9):879-885.
82. Tonelli M., et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112(17):2627-2633.
83. Kestenbaum B., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16(2):520-528.
84. Eddington H., et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5(12):2251-2257.
85. Block G.A., et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31(4):607-617.
86. Block G.A., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15(8):2208-2218.
87. Slinin Y., Foley R.N., Collins A.J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005, 16(6):1788-1793.
88. Noordzij M., et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005, 46(5):925-932.
89. Kalantar-Zadeh K., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70(4):771-780.
90. Tentori F., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52(3):519-530.
91. Strozecki P., et al. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001, 23(1):115-126.
92. Voormolen N., et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007, 22(10):2909-2916.
93. Gutierrez O.M., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359(6):584-592.
94. Jean G., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009, 24(9):2792-2796.
95. Kirkpantur A., et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011, 26(4):1346-1354.
96. Mirza M.A., et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205(2):385-390.
97. Yilmaz M.I., et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010, 78(7):679-685.
98. Li Y.C., et al. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110(2):229-238.
99. O'Connell T.D., et al. 1, 25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997, 272(4 Pt 2). H1751-8.
100. London G.M., et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18(9):1731-1740.
101. Goodman W.G., et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004, 43(3):572-579.
102. Vanholder R., et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005, 20(6):1048-1056.
103. Nishioka T., et al. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol 1999, 33(7):1870-1878.
104. Porter T.R., et al. Intravascular ultrasound study of angiographically mildly diseased coronary arteries. J Am Coll Cardiol 1993, 22(7):1858-1865.
105. Braun J., et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996, 27(3):394-401.
106. Bellasi A., et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006, 70(9):1623-1628.
107. Group, KDIGOKCMW, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, (Suppl. 113). S1-S130.
108. Goodman W.G., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342(20):1478-1483.
109. Schwarz U., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000, 15(2):218-223.
110. Goldsmith D.J., et al. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997, 77(1):37-43.
111. Meema H.E., Oreopoulos D.G., deVeber G.A. Arterial calcifications in severe chronic renal disease and their relationship to dialysis treatment, renal transplant, and parathyroidectomy. Radiology 1976, 121(2):315-321.
112. Raggi P., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 2002, 39(4):695-701.
113. Kramer H., et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005, 16(2):507-513.
114. Blacher J., et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38(4):938-942.
115. Block G.A., et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71(5):438-441.
116. Adeney K.L., et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009, 20(2):381-387.
117. Foley R.N., et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009, 20(2):397-404.
118. Kendrick J., et al. Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2010, 106(4):564-568.
119. Kendrick J., Kestenbaum B., Chonchol M. Phosphate and cardiovascular disease. Adv Chronic Kidney Dis 2011, 18(2):113-119.
120. Block G.A., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68(4):1815-1824.
121. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62(1):245-252.
122. Cozzolino M., et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002, 13(9):2299-2308.
123. Giachelli C.M. The emerging role of phosphate in vascular calcification. Kidney Int 2009, 75(9):890-897.
124. Li X., Yang H.Y., Giachelli C.M. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006, 98(7):905-912.
125. Sugita A., et al. Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis. J Biol Chem 2011, 286(4):3094-3103.
126. Rutherford W.E., et al. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest 1977, 60(2):332-341.
127. Young E.W., et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004, 44(5 Suppl. 2):34-38.
128. Ramirez J.A., et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 1986, 30(5):753-759.
129. Kayne L.H., et al. Analysis of segmental phosphate absorption in intact rats. A compartmental analysis approach. J Clin Invest 1993, 91(3):915-922.
130. Sandberg A.S., et al. Extrusion cooking of a high-fibre cereal product. 1. Effects on digestibility and absorption of protein, fat, starch, dietary fibre and phytate in the small intestine. Br J Nutr 1986, 55(2):245-254.
131. Kalantar-Zadeh K., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5(3):519-530.
132. Murphy-Gutekunst L. Hidden phosphorus: where do we go from here?. Journal of Renal Nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2007, 17(4):e31-e36.
133. Calvo M.S., Park Y.K. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. J Nutr 1996, 126(Suppl. 4):1168S-1180S.
134. Uribarri J. Phosphorus additives in food and their effect in dialysis patients. Clin J Am Soc Nephrol 2009, 4(8):1290-1292.
135. Bell R.R., et al. Physiological responses of human adults to foods containing phosphate additives. J Nutr 1977, 107(1):42-50.
136. Uribarri J., Calvo M.S. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?. Semin Dial 2003, 16(3):186-188.
137. Murphy-Gutekunst L. Hidden phosphorus in popular beverages. Nephrol Nurs J 2005, 32(4):443-445.
138. Sherman R.A., Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol 2009, 4(8):1370-1373.
139. Sullivan C., et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009, 301(6):629-635.
140. Sullivan C.M., Leon J.B., Sehgal A.R. Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients. J Ren Nutr 2007, 17(5):350-354.
141. Shinaberger C.S., et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 2006, 48(1):37-49.
142. Shinaberger C.S., et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr 2008, 88(6):1511-1518.
143. Noori N., et al. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010, 5(4):683-692.
144. Taylor L.M., et al. Dietary egg whites for phosphorus control in maintenance haemodialysis patients: a pilot study. J Ren Care 2011, 37(1):16-24.
145. Sherman R.A., Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis 2009, 54(1):18-23.
146. Fouque D., et al. Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 2008, 23(9):2902-2910.
147. Moe S.M., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6(2):257-264.
148. Gutierrez O.M., Wolf M. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Semin Dial 2010, 23(4):401-406.
149. Karp H.J., et al. Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach. Calcif Tissue Int 2007, 80(4):251-258.
150. DeSoi C.A., Umans J.G. Phosphate kinetics during high-flux hemodialysis. J Am Soc Nephrol 1993, 4(5):1214-1218.
151. Kooienga L. Phosphorus balance with daily dialysis. Semin Dial 2007, 20(4):342-345.
152. Spalding E.M., Chamney P.W., Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int 2002, 61(2):655-667.
153. Hou S.H., et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991, 18(2):217-224.
154. Minutolo R., et al. Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 2002, 13(4):1046-1054.
155. Ayus J.C., et al. Effects of short daily vs. conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005, 16(9):2778-2788.
156. Mucsi I., et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998, 53(5):1399-1404.
157. Culleton B.F., et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007, 298(11):1291-1299.
158. Bugeja A., et al. In-center nocturnal hemodialysis: another option in the management of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(4):778-783.
159. Messa P., et al. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 1998, 13(Suppl. 6):43-48.
160. Badve S.V., et al. Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics. Clin J Am Soc Nephrol 2008, 3(6):1711-1717.
161. Sedlacek M., Dimaano F., Uribarri J. Relationship between phosphorus and creatinine clearance in peritoneal dialysis: clinical implications. Am J Kidney Dis 2000, 36(5):1020-1024.
162. Kuhlmann M.K. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010, 29(2):137-144.
163. Malluche H.H. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002, 17(Suppl. 2):21-24.
164. Parkinson I.S., et al. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1979, 1(8113):406-409.
165. Salusky I.B., et al. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991, 324(8):527-531.
166. Wills M.R., Savory J. Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet 1983, 2(8340):29-34.
167. Emmett M., et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991, 17(5):544-550.
168. Navaneethan S.D., et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 54(4):619-637.
169. Sheikh M.S., et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989, 83(1):66-73.
170. Kurz P., et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994, 46(3):855-861.
171. Schaefer K., Umlauf E., von Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992, 19(5):460-464.
172. Delmez J., et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007, 68(6):386-391.
173. Pai A.B., Shepler B.M. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009, 29(5):554-561.
174. Chertow G.M., et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999, 14(12):2907-2914.
175. Chertow G.M., et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997, 29(1):66-71.
176. Goldberg D.I., et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998, 13(9):2303-2310.
177. Slatopolsky E.A., Burke S.K., Dillon M.A. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999, 55(1):299-307.
178. Ferramosca E., et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005, 149(5):820-825.
179. Suki W.N., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72(9):1130-1137.
180. Caglar K., et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008, 3(1):61-68.
181. Koiwa F., et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005, 9(4):336-339.
182. Qunibi W., et al. A 1-year randomized trial of calcium acetate vs. sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008, 51(6):952-965.
183. Barreto D.V., et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008, 110(4). c273-83.
184. Tonelli M., Pannu N., Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010, 362(14):1312-1324.
185. Tonelli M., et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007, 22(10):2856-2866.
186. Raggi P., et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010, 5(Suppl. 1):S31-S40.
187. St Peter W.L., et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008, 51(3):445-454.
188. Albaaj F., Hutchison A.J. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract 2005, 59(9):1091-1096.
189. Chiang S.S., Chen J.B., Yang W.C. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005, 63(6):461-470.
190. Finn W.F., Joy M.S., Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004, 62(3):193-201.
191. Shigematsu T., Negi S. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant 2011.
192. Finn W.F. Lanthanum carbonate vs. standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006, 65(3):191-202.
193. Freemont A.J., Hoyland J.A., Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005, 64(6):428-437.
194. Malluche H.H., et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008, 70(4):284-295.
195. Shoben A.B., et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19(8):1613-1619.
196. Teng M., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349(5):446-456.
197. Teng M., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16(4):1115-1125.
198. Slatopolsky E., et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984, 74(6):2136-2143.
199. Quarles L.D., et al. Prospective trial of pulse oral vs. intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994, 45(6):1710-1721.
200. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995, 26(5):852-860.
201. Sprague S.M., et al. Paricalcitol vs. calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003, 63(4):1483-1490.
202. Maung H.M., et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001, 37(3):532-543.
203. Nemeth E.F., et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004, 308(2):627-635.
204. Block G.A., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004, 350(15):1516-1525.
205. Lindberg J.S., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003, 63(1):248-254.
206. Moe S.M., et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005, 67(2):760-771.
207. Quarles L.D., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003, 14(3):575-583.
208. Block G.A., et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008, 23(7):2311-2318.
209. Raggi P., et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011, 26(4):1327-1339.